Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective Study Assessing the Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir (G/P) in Patients with Chronic Hepatitis C Virus Infection within the German Hepatitis C-Registry (DHC-R)

Trial Profile

A Multicenter, Prospective Study Assessing the Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir (G/P) in Patients with Chronic Hepatitis C Virus Infection within the German Hepatitis C-Registry (DHC-R)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Nov 2018 Results of a retrospective analysis assessing Drug-Drug Interaction Potential of Glecaprevir/ Pibrentasvir (n=19,042) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
  • 07 Oct 2018 Results presented at the IDWeek 2018
  • 10 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top